Crizotinib, a FDA approved drug for treatment of Non-Small Cell Lung Carcinoma (NSCLC) patients with rearranged ROS1 was used to treat these resistant cells and showed a moderate effect compared to the pyrazole ROS1 inhibitor (Figure S3). The gene discussed is ROS1; the disease is non-small cell lung carcinoma.